Glycogen-targeting subunits of protein phosphatase-1 facilitate interaction of the phosphatase with enzymes of glycogen metabolism. We have shown that overexpression of one member of the family, protein targeting to glycogen (PTG), causes large increases in glycogen storage in isolated hepatocytes or intact rat liver. In the current study, we have compared the metabolic and regulatory properties of PTG (expressed in many tissues), with two other members of the gene family, G L (expressed primarily in liver) and G M /R Gl (expressed primarily in striated muscle). Adenovirus-mediated expression of these proteins in hepatocytes led to the following key observations. 1) G L has the highest glycogenic potency among the three forms studied. 2) Glycogen synthase activity ratio is much higher in G Loverexpressing cells than in PTG or G M /R Gl -overexpressing cells. Thus, at moderate levels of G L overexpression, glycogen synthase activity is increased by insulin treatment, but at higher levels of G L expression, insulin is no longer required to achieve maximal synthase activity. In contrast, cells with high levels of PTG overexpression retain dose-dependent regulation of glycogen synthesis and glycogen synthase enzyme activity by insulin. 3) G L -and G M /R Gl -overexpressing cells exhibit a strong glycogenolytic response to forskolin, whereas PTG-overexpressing cells are less responsive. This difference may be explained in part by a lesser forskolin-induced increase in glycogen phosphorylase activity in PTG-overexpressing cells. Based on these results, we suggest that expression of either G L or G M /R Gl in liver of diabetic animals may represent a strategy for lowering of blood glucose levels in diabetes.
An emerging concept of recent years is that glycogen metabolism in mammalian cells is regulated not only by familiar enzymes such as glycogen phosphorylase and glycogen synthase, but also by a family of glycogen-targeting subunits of protein phosphatase-1 (PP1) 1 (1) (2) (3) (4) (5) (6) (7) (8) (9) . PP1 causes stimulation of glycogen synthase and suppression of glycogen phosphorylase and phosphorylase kinase activities by dephosphorylation of these enzymes. Glycogen-targeting subunits bind directly to the glycogen particle, and possibly to glycogen synthase, phosphorylase kinase, and glycogen phosphorylase (1) (2) (3) (4) (5) . Based on these properties, it has been suggested that glycogen-targeting subunits function as a "scaffold" that assembles and facilitates the regulation of enzymes of glycogen metabolism (4, 5) .
Four members of the family of glycogen-targeting subunits of PP1 have been identified. The first to be characterized was a 126-kDa protein that is expressed in heart and skeletal muscle. The cDNA encoding this protein, initially termed R Gl (for glycogen-binding regulatory subunit), was cloned from a rabbit muscle library (1) . This targeting subunit is also know as G M . Therefore, in what follows, it will be referred to as G M /R Gl . Binding of G M /R Gl to PP1 enhances dephosphorylation of glycogen synthase and causes activation of glycogenesis. The ability of G M /R Gl to promote glycogen synthesis is hormonally regulated. Thus, glycogenolytic agents such as adrenaline cause phosphorylation of rabbit R Gl at serine 67 (corresponding to serine 65 in the human isoform), and, in some reports, also serine 48 (corresponding to serine 46 in the human protein), resulting in dissociation and thus inactivation of the G M /R Gl -PP1 complex (5, 10) . A second isoform, G L , is a 33-kDa protein that is expressed primarily in liver, and appears to be regulated allosterically by binding to phosphorylase a, but not by phosphorylation and dephosphorylation (2) . Phosphorylase a binds to the C-terminal tail of G L , resulting in inhibition of the glycogen synthase and glycogen phosphorylase phosphatase activities of PP1 (2, 11) . A recently discovered 36-kDa isoform known as PTG (protein targeting to glycogen) (4), or PPP1R5 (3) also activates glycogen synthesis, but is distinct from G L in that it has a wide tissue distribution. Finally, an isoform termed PPP1R6 has recently emerged, which, like PTG, is found in many tissues (10) .
Hepatic glycogen stores are reduced in concert with an increase in net hepatic glucose production in all forms of human diabetes studied to date (12) (13) (14) . We have been investigating gene therapy strategies for repairing dysfunctional regulation of hepatic glucose disposal and production in type 2 diabetes. One approach that has been tried by our group and others is to increase the activity of the glucose phosphorylating enzyme glucokinase in liver (15) (16) (17) . Overexpression of glucokinase in rats (15) or mice (16, 17) does in fact lower blood glucose levels and increase hepatic glycogen storage. However, in the rat studies, these effects were accompanied by a large increase in circulating free fatty acids and triglycerides (15) , suggesting that this approach could exacerbate the hyperlipidemia typically found in type 2 diabetes. Increased expression of glycogentargeting subunits could conceivably represent an alternative strategy, since these proteins should specifically enhance glucose disposal by activating glycogen synthesis. Consistent with this idea, we recently reported that adenovirus-mediated overexpression of PTG in hepatocytes isolated from fasted rats results in profound activation of glycogen synthesis (6) . We have also shown that overexpression of PTG in liver of normal rats enhances hepatic glucose disposal without affecting lipid homeostasis (18) . However, PTG-overexpressing liver cells were found to be largely refractory to glucagon or forskolinmediated activation of glycogenolysis, raising concerns that overexpression of this protein could result in a glycogen storage disease.
The purpose of the current study was to investigate whether glycogen-targeting subunits of PP1 other than PTG might be more suitable candidates for improving hepatic glucose disposal. This was accomplished by construction of recombinant adenoviruses containing the cDNAs encoding PTG, G L , and G M /R Gl and comparison of the metabolic and regulatory properties of the expressed gene products in isolated rat hepatocytes.
MATERIALS AND METHODS

Construction of Recombinant
Adenoviruses-Rat G L and rabbit G M / R Gl (1) cDNAs were cloned into the pACCMV-pLpA plasmid and recombinant adenoviruses (AdCMV-G L and AdCMV-G M /R Gl ) were produced using previously described methods (6, 19) . The rat G L cDNA was prepared by polymerase chain reaction amplification of a rat liver cDNA library using 5Ј-CGG GGT ACC AAC TTC TCT TCA GGC TCT CCC ATG-3Ј (sense, nucleotides 1-23) and 5Ј-CGC GGA TCC CGC GTT CTC ACC TCC ACC TTG ATC-3Ј(antisense, nucleotides 980 -1003) based on the published rat G L sequence (2) . Construction of a recombinant adenovirus containing the mouse PTG cDNA has been described elsewhere (6) .
Hepatocyte Isolation and Viral Treatment-Primary hepatocytes were prepared from overnight fasted male Wistar rats by collagenase perfusion (20) . Cells were suspended in Dulbecco's modified Eagle's medium (DMEM, Life Technologies, Inc.) supplemented with 25 mM glucose, 10% fetal bovine serum, 100 nM insulin (Life Technologies, Inc.), 100 nM dexamethasone, 2 mM sodium pyruvate (Sigma), and antibiotics (2 units/ml penicillin; 2 g/ml streptomycin) and seeded onto collagen-coated plates at a cell density of 8 ϫ 10 4 cells/cm 2 . After attachment (90 min at 37°C), hepatocytes were treated for 1 h with AdCMV-PTG or AdCMV-G L , generally at a multiplicity of infection (m.o.i.) of 5, except where indicated in figure legends. Initial studies with AdCMV-G M /R Gl indicated that expression of this glycogen-targeting subunit was less efficient than G L or PTG in hepatocytes. Thus, this virus was used at a m.o.i. of 15. Viruses were diluted in 2 ml of "culture medium" consisting of DMEM containing 1 mM glucose, 0.07% bovine serum albumin (Sigma), 1 nM insulin, 10 nM dexamethasone, 2 mM sodium pyruvate, and antibiotics. After viral treatment, cells were washed once with phosphate-buffered saline and incubated, unless otherwise stated, for a further period of 24 h in culture medium containing variable glucose and other additives as indicated in figure legends. For longer incubation times, fresh medium was replenished after the first 24 h of culture.
Measurement of Expression of Glycogen-targeting Subunits in Liver by
Semiquantitative Multiplex RT-PCR-The procedure used was based on methods described previously (18, 21) . Total RNA was extracted from hepatocytes using the RNeasy kit (Qiagen Inc., Valencia, CA) according to the manufacturer's instructions. Total RNA was diluted to 0.2 g/l in RNase-free water. First-strand cDNA was prepared using 1 g of total RNA, using the Superscript RT kit and random hexamer primers (Life Technologies, Inc.) according to the manufacturer's instructions. The cDNA was diluted 1:6 in distilled water, and PCR was carried out using 3 l of the diluted cDNA and a PCR mix containing Taq DNA polymerase (2.5 units) and buffer (Promega Corp., Madison, WI), dNTP mix (final concentrations of 40 mM amounts of each dNTP, except dCTP, which was present at 20 mM) (Life Technologies, Inc.), and 1.25 Ci of [␣-
33 P]dCTP (2000 Ci/mmol) (NEN Life Science Products) in a 25-l reaction volume, following the instructions from Promega. Four primer sets (5 pmol of each primer) were included in each reaction. The first set, specific for mouse PTG (accession no. U89924), generates a 188-base pair PCR fragment, and the second set, specific for rat G L (accession no. S80360), generates a 232-base pair PCR as described previously (18) . The third set, specific for rabbit G M /R Gl (accession no. M65109; 5Ј-primer (5Ј-CTCAAAGGAAGATCT-TATGCAAC-3Ј) and 3Ј-primer (5Ј-GTTTGCCAGTCATCTAAGGAC-3Ј)), generates a 162-base pair PCR fragment, and the fourth set, specific for ␣-tubulin (accession no. J00797; 5Јprimer (5Ј-GCGTGAGT-GTATCTCCATCCA-3Ј) and 3Ј-primer (5Ј-GGTAGGTGCCAGTGC-GAACTT-3Ј)), generates a 250-base pair PCR fragment and serves as an internal standard. PCR conditions were an initial incubation at 95°C for 2 min, followed by 18 cycles of 94°C for 45 s, 55°C for 45 s, and 72°C for 45 s. The final PCR reactions were mixed with 98% formamide denaturing loading buffer and separated on a 6% (w/v) polyacrylamide gel, containing 7 M urea. The gel was subsequently dried and exposed to a PhosphorImager screen, and the resulting scan was analyzed using ImageQuant from Molecular Dynamics (Sunnyvale, CA). To compare expression levels between the different glycogen-targeting subunits, we have accounted for differences in incorporation of [ 33 P]dCTP for each amplified gene product. To do this, we divided the integrated volume for each band with the number of G and C nucleotides in the amplified sequence, which is 98 for PTG, 123 for G L , and 58 for G M /R Gl .
Glycogen Measurements-Glycogen content was measured by scraping cells into 30% KOH, boiling the extract for 15 min, and centrifuging at 5,000 ϫ g for 5 min. Glycogen in the cleared supernatant was measured as described (22) . Protein content in the samples was determined by method of Bradford (23), using the Bio-Rad assay kit.
Enzyme Activity Assays-Glycogen synthase activity was assayed as described previously by measuring the incorporation of [
14 C]UDP-glucose into glycogen, in the presence or absence of 6.6 mM glucose 6-phosphate (Glc-6-P) (24) . The activity measured in the absence of Glc-6-P represents the active form of the enzyme, whereas the activity in the presence of 6.6 mM Glc-6-P represents total activity. The ratio of these two activities is known as the glycogen synthase "activity ratio" and is an estimate of the degree of activation of the enzyme. Activated glycogen phosphorylase (phosphorylase a) activity was assayed by measuring incorporation of [
14 C]glucose 1-phosphate into glycogen as described (25) . 200 g of protein from a crude cell extract was added to 40 l of assay mix containing 200 mM potassium fluoride, 1% glycogen, 10 mM caffeine, 100 mM glucose 1-phosphate, and [
14 C]glucose 1-phosphate (3000 cpm/l, specific activity of 234 mCi/mmol).
Immunoblot Analyses-PTG and G M /R Gl protein levels were measured by immunoblot assay, using purified His-tagged PTG (containing 23 His residues) or a 67-kDa fragment of G M /R Gl as internal standards for quantification and a previously described anti-PTG antibody (4) or an antibody raised against a purified fragment (amino acids 1-453) of G M /R Gl .
For determination of total glycogen phosphorylase or glycogen phosphorylase a levels by immunoblot analysis, hepatocytes were lysed at 4°C in a buffer consisting of 50 mM Hepes, pH 7.5, 150 mM NaCl, 1% Triton X-100, 100 mM NaF, 2 mM sodium vanadate, and protease inhibitors (0.2 mg/ml phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 5 g/ml leupeptin). For analysis of PP1 levels, extracts were prepared in a buffer containing 50 mM Tris-HCl, 5 mM EGTA, 5 mM EDTA, 1% Triton X-100, and protease inhibitors as described above.
Lysates were centrifuged at 600 ϫ g, and the supernatants were col- lected. Extract aliquots containing 50 g of protein were resolved on a 10% SDS-polyacrylamide gel and transferred onto polyvinylidene difluoride membranes. After blocking the membranes for 1 h in Tris-buffered saline containing 0.2% Igepal CA-630 and 4% nonfat dry milk, the blots were incubated with either an affinity-purified anti-phosphorylase a antibody at a 1:500 dilution, a crude antiserum that recognizes both phosphorylase a and b (measures total phosphorylase levels) at 1:1000 dilution, or an antibody that recognizes all forms of PP1 (Transduction Laboratories, Lexington, KY) at a 1:1000 dilution at 4°C overnight. Membranes were then incubated with a secondary antibody conjugated to horseradish peroxidase and visualized using an enhanced chemiluminescence (ECL) detection kit.
The anti-phosphorylase a antibody was raised in rabbits against the peptide EKRRQI-pS-IRGIVG of the rat liver phosphorylase sequence, whereas the antibody against total glycogen phosphorylase (recognizing both the a and b forms) was raised against a peptide from the extreme N terminus of the rat liver glycogen phosphorylase sequence, MAKPLT-DQEKRRQISIR. The latter antibody was found to be highly specific as a crude antiserum and was not affinity-purified. The anti-phosphorylase a antibody was diluted 1:1 with PBS, incubated with immobilized phosphopeptide, and eluted with 100 mM glycine (pH 2.5). After neutralization with 100 mM Tris (pH 8.8), the eluate was passed over immobilized EKRRQISIRGIVG peptide, to remove anti-phosphorylase b antibody. The flow through, which contains the phosphorylase a-specific antibody, was collected and concentrated with an Amicon-10 filtration device. Both antibodies were then tested by immunoblot analysis against purified phosphorylase a and phosphorylase b (Sigma).
RESULTS
Expression of Glycogen-targeting Subunits in Hepato-
cytes-In order to evaluate glycogen-targeting subunit expression, a multiplex PCR approach was used to measure the levels of G L , PTG, and G M /R Gl mRNAs in rat hepatocytes 24 h after exposure to the various recombinant viruses, and glycogen content was measured in parallel hepatocyte samples. The studies depicted in the left-hand portions of Fig. 1 (A-C) were conducted with viral titers of 5, 5, and 15 m.o.i. for AdCMV-PTG, AdCMV-G L , and AdCMV-G M /R Gl , respectively. The left panel of Fig. 1A shows autoradiographs from four independent experiments, two with hepatocytes cultured at low glucose (1 mM) and two with hepatocytes at high glucose (20 mM). Since no significant effect of glucose concentration on adenovirus-mediated expression of any of the glycogen-targeting subunits was noted, densitometric data were combined for the four separate experiments and summarized quantitatively as shown in the left panel of Fig. 1B . This analysis shows that the levels of PTG and G L expression achieved in AdCMV-G L and AdCMV-PTGtreated cells were equivalent. Endogenous G L was detectable in untreated rat hepatocytes, whereas endogenous PTG was not detected, since amplification of PTG was performed with primers specific to the mouse cDNA, which is the form contained in the AdCMV-PTG virus. Densitometric analysis reveals that G L is overexpressed by approximately 20-fold in AdCMV-G L expressing cells relative to untreated control cells. G M /R Gl mRNA was expressed at approximately 35% the levels of G L or PTG, despite the fact that 3 times the number of AdCMV-G M /R Gl viral particles were used relative to AdCMV-G L or AdCMV-PTG.
At the levels of expression described in Fig. 1 (A and B) , G L -overexpressing cells had significantly higher levels of glycogen than PTG-overexpressing cells, whereas AdCMV-G M /R Gl treated cells contained only 11% and 7% of the glycogen in Ad-CMV-PTG or AdCMV-G L -treated cells respectively (Fig. 1C, left) .
In order to determine whether the difference in glycogenic potency of G L and G M /R Gl was due to intrinsic differences in biologic activities of the expressed proteins or simply related to different levels of transgene expression, we performed a second set of studies at a reduced level of G L overexpression. As shown in the right-hand portions of Fig. 1 (A and B) , (Fig. 1C) . Thus, G L has a clearly enhanced intrinsic capacity to promote glycogen synthesis relative to G M /R Gl .
The low potency of G M /R Gl for stimulation of glycogenesis was not overcome by adding even higher titers of AdCMV-G M / R Gl virus up to 120 m.o.i. (data not shown). To determine if the limited glycogenic effect of increasing titers of the AdCMV-G M / R Gl virus was related to a ceiling in production of the recombinant protein, immunoblot analysis was performed on cells overexpressing PTG or G M /R Gl , using purified recombinant proteins as internal quantification standards. As shown in Fig (Fig. 2B) . In contrast, increasing the dose of AdCMV-G M /R Gl from 15 to 30 m.o.i. caused a clear increase in immunodetectable G M /R Gl protein without an increase in glycogen content (Fig. 2B) . These experiments define an inherent limitation in glycogenic effect of overexpressed G M /R Gl in hepatocytes that is independent of the level of expression of the recombinant protein. All experiments that follow in this study were conducted at levels of PTG, G L , and G M /R Gl overexpression described in the left-hand portions of Fig. 1 (A and B) , except in Fig. 6 as noted.
Glucose Concentration Dependence of Glycogen Synthesis in Hepatocytes Overexpressing Various Glycogen-targeting Subunits-We have previously shown that overexpression of PTG in hepatocytes results in enhanced glycogen synthesis at low glucose or even in its absence in the culture medium (6) . To determine whether this property is shared by other glycogentargeting subunits, glycogen content was measured 24 h after viral treatment in cells cultured at different glucose concentrations. The time point for these experiments was chosen based on a comparison of cells harvested at 12, 24, 36, and 48 h after viral treatment. These studies revealed that glycogen synthesis was in a linear phase at low glucose (1 mM), or approaching maximum at high glucose (20 mM) in cells overexpressing each of the glycogen-targeting subunits at the 24 h time point (data not shown). As shown in Fig. 3 , G L and PTG overexpression caused significant accumulation of glycogen in the absence of glucose or at low concentrations, but also allowed potent activation of glycogen accumulation as glucose concentrations were raised. Glucose increased glycogen synthesis more effectively in G L -overexpressing cells than in cells overexpressing PTG, these effects becoming apparent at glucose concentrations of Ն3 mM. At 20 mM glucose, G L -overexpressing cells accumulated 54% more glycogen that PTG-overexpressing cells. In contrast to G L and PTG, overexpression of G M /R Gl caused no significant increases in glycogen synthesis at low glucose, whereas high glucose induced a maximal increase of glycogen content of 3.3-fold relative to control cells, only 7.5% of the amount in G L -overexpressing cells.
Glycogen Synthase and Glycogen Phosphorylase Enzymatic Activities in Hepatocytes Expressing Different Glycogen-target-
ing Subunits-We next examined whether the effects of glycogen-targeting subunits on glycogen accumulation could be explained by corresponding effects on enzymes of glycogen metabolism. In cells incubated at 1 mM glucose and 1 nM insulin, we found that G L overexpression caused a 6.7-fold increase in glycogen synthase activity ratio relative to control hepatocytes, significantly greater than the 3.1-and 1.9-fold increases observed in cells overexpressing PTG or G M /R Gl , respectively (Fig. 4A) . Furthermore, although overexpression of all three glycogen-targeting subunit isoforms lowered total glycogen phosphorylase activity in hepatocytes (by 25-46%), this trend only achieved statistical significance in G L -overexpressing cells (Fig. 4B) . These effects were not due to changes in expression of PP1, since PTG-, G L -, and G M /R Gl -overexpressing cells contained the same levels of the phosphatase as untreated control cells, as measured by immunoblot analysis (data not shown). These data on glycogen synthase and glycogen phosphorylase activities are thus consistent with the higher levels of glycogen found in G L -overexpressing cells compared with PTG-or G M / R Gl -overexpressing cells.
Differential Regulation of Glycogen Synthesis by Insulin in Hepatocytes Expressing Different Glycogen-targeting Subunits-It has been
proposed that glycogen-targeting subunits may participate in insulin regulation of glycogen synthesis (5), but the effects of overexpression of different family members on insulin-regulated glycogen accumulation has never been compared. We therefore overexpressed G L , PTG, and G M /R Gl in hepatocytes from fasted rats, and analyzed glycogen accumulation in the presence and absence of different concentrations of insulin (Fig. 5) . At the levels of overexpression of each of the isoforms represented in the left-hand portion of Fig. 1 , insulin had no effect on glycogen accumulation in G L -or G M /R Gl -overexpressing cells at 20 mM glucose. In contrast, insulin caused glycogen synthesis to increase in a dose-dependent manner in   FIG. 4. Changes in glycogen synthase and glycogen phosphorylase a activities induced by PTG, G L , or G M /R G1 overexpression in hepatocytes. Hepatocytes were isolated from fasted rats, treated with the indicated adenoviruses for 1 h, cultured in DMEM containing 1 mM glucose and 1 nM insulin for 24 h, and harvested for determination of glycogen synthase (panel A) and glycogen phosphorylase a (panel B) enzyme activities as described under "Materials and Methods." Note that data for glycogen synthase are expressed as the activity ratio, defined as the ratio of the activity measured in the absence of glucose 6-phosphate relative to activity in the presence of 6.6 mM glucose 6-phosphate. For both panels, results represent the mean Ϯ S.E. for five independent experiments, each performed in duplicate. The symbols *, **, and *** indicate that differences between cells treated with adenovirus and cells left untreated are statistically significant, with p Ͻ 0.05, p Ͻ 0.01, and p Ͻ 0.001, respectively. PTG-overexpressing cells studied at 20 mM glucose. Another way of describing these findings is that addition of 100 nM insulin to PTG-overexpressing hepatocytes cultured at high glucose allowed them to become equivalent in glycogenic capacity to G L -overexpressing cells.
Consistent with the results shown in Fig. 5 , untreated hepatocytes or hepatocytes with overexpressed PTG exhibited significant increases (60%) in glycogen synthase activity ratio in response to 100 nM insulin, whereas glycogen synthase activity in G L -overexpressing cells was unaffected by addition of the hormone (Fig. 6) . However, the lack of effect of insulin in the latter cells is likely explained by a level of G L overexpression that causes complete activation of glycogen synthase, such that no further effect of insulin can be observed. Consistent with this interpretation, cells treated with 2.5 rather than 5 m.o.i. of AdCMV-G L virus were able to activate glycogen synthase in response to 100 nM insulin by 137% (Fig. 6) . However, the glycogen synthase activity ratios obtained in these cells in the absence (0.32 Ϯ 0.01) and presence (0.76 Ϯ 0.02) of 100 nM insulin were clearly higher than the corresponding values in cells treated with 5 m.o.i. of AdCMV-PTG (0.17 Ϯ 0.02 and 0.27 Ϯ 0.02, respectively), confirming the enhanced potency of G L for regulation of glycogen synthase activity relative to other glycogen-targeting subunits.
Differential Regulation of Glycogenolysis by Forskolin in Hepatocytes Expressing
Different Glycogen-targeting Subunits-We recently reported that cells overexpressing PTG were largely refractory to activation of glycogenolysis by agents such as forskolin and glucagon (6) , raising the issue of whether other glycogen-targeting subunits would have similar effects. To test this, we overexpressed PTG, G L , and G M /R Gl in hepatocytes from fasted rats and allowed glycogen to accumulate in the presence of 1 or 20 mM glucose for 24 h. Thereafter, cells were incubated in the presence or absence of 25 M forskolin for 4 h, and then harvested for measurement of glycogen content. As shown in Fig. 7 , nearly all of the glycogen that accumulated in control or G M /R Gl expressing hepatocytes incubated at 20 mM glucose was degraded in response to forskolin, although G M /R Gl -overexpressing hepatocytes accumulated 3 times more glycogen than controls prior to drug treatment. In agreement with our previous observations (6, 18), PTG-overexpressing hepatocytes exhibited a loss of only 38 and 21% of their glycogen during the 4 h treatment with forskolin at 1 or 20 mM glucose, respectively. In contrast, forskolin treatment of G Loverexpressing hepatocytes resulted in degradation of 74% and 37% of the glycogen at 1 and 20 mM glucose, respectively. The mass of glycogen degraded was also much larger in G L -overexpressing cells than in PTG-overexpressing cells (413 g/mg protein/4 h versus 145 g/mg protein/4 h, respectively, in cells cultured at 20 mM glucose). Thus, overexpression of G L or G M /R Gl in hepatocytes confers improved glycogenic capacity coupled with retention of sensitivity to forskolin, whereas PTG overexpression enhances glycogen synthesis but with clear resistance to regulation by this glycogenolytic agent. . Cells were then harvested, and glycogen synthase activity ratio was determined as described in the legend to Fig. 4 . Results represent the mean Ϯ S.E. for three independent experiments, except for treatment with the half-dose of AdCMV-G L , which comprises one set of experiments performed in triplicate. The symbol * indicates that glycogen synthase activity ratio was higher in cells cultured with insulin than cells cultured in the absence of the hormone for a given viral treatment, with a significance of p Ͻ 0.05. legend at left of figure) . At the end of this period, cells were collected for measurement of glycogen content. Results represent the mean Ϯ S.E. for five or six independent experiments, each performed in triplicate. The symbols *, **, and *** indicate that glycogen levels were decreased in cells incubated with forskolin relative to cells incubated without this agent for a given glucose concentration and viral treatment, with levels of significance of p Ͻ 0.05, p Ͻ 0.005, and p Ͻ 0.001, respectively. similar decreases of 65%, 58%, and 62% in glycogen synthase activity ratio in PTG-, G L -, or G M /R Gl -overexpressing hepatocytes, respectively (Fig. 8A) . In contrast, forskolin treatment caused significant increases in glycogen phosphorylase a activity of 120% (p ϭ 0.01) and 110% (p ϭ 0.04) in G L -or G M /R Gloverexpressing cells, respectively, but resulted in a statistically insignificant 40% increase in PTG-overexpressing cells (p ϭ 0.19) (Fig. 8B) . This differential regulation of glycogen phosphorylase activity may contribute to the resistance to glycogenolytic stimuli observed in PTG-overexpressing cells.
Regulation of Glycogen Synthase and Glycogen Phosphorylase Activities in Hepatocytes with
Levels of Total Phosphorylase and Phosphorylase a in Hepatocytes with Overexpressed Glycogen-targeting Subunits-Fi-
nally, we performed immunoblot analysis to determine whether the differential effects of forskolin on glycogen phosphorylase activity noted in Fig. 8B were related to changes in the levels of immunodetectable total glycogen phosphorylase (a ϩ b forms) or glycogen phosphorylase a. In the presence of 20 mM glucose, forskolin treatment of cells overexpressing G L , PTG, or G M /R Gl resulted in similar increases in immunodetectable phosphorylase a, whereas forskolin had no effect on total phosphorylase levels (Fig. 9) . Thus, the data of Fig. 8 showing less efficient activation of glycogen phosphorylase activity by forskolin in PTG-overexpressing cells than in G L -or G M /R Gloverexpressing cells is not readily explained by changes in total phosphorylase or phosphorylase a levels, suggesting the operation of a more complicated regulatory mechanism.
DISCUSSION
In this study, we have compared the metabolic and regulatory properties of overexpressed glycogen-targeting subunits of protein phosphatase-1 in isolated hepatocytes. We find that the three forms studied, PTG, G L , and G M /R Gl , can be clearly differentiated in terms of their metabolic effects and responses to exogenous regulators of glycogen metabolism. Key findings of this work include the following. 1) G L has the highest glycogenic potency among the three forms studied, and this effect is correlated with its greater capacity for conversion of glycogen synthase to its intrinsically active form (Glc-6-P-independent activity). 2) When G L is overexpressed at high levels, glycogen synthesis can occur in an insulin-independent fashion in hepatocytes. When PTG is overexpressed to equivalent levels, glycogen synthesis and glycogen synthase enzyme activity are regulated by insulin in a dose-dependent manner, such that PTG becomes equal to G L in glycogenic potency in the presence of the hormone. 3) G L -and G M /R Gl -overexpressing cells are highly responsive to the glycogenolytic effects of forskolin, whereas PTG-overexpressing cells are less responsive. This appears to be due, at least in part, to differential regulation of glycogen phosphorylase activity in cells expressing PTG relative to cells expressing G L or G M /R Gl .
Our findings can be partially interpreted in terms of what is known about the structure of the PTG, G L , and G M /R Gl proteins. Thus, ␤-adrenergic agonist-mediated phosphorylation of serine 48 and serine 67 (using the numbering for the rabbit R Gl sequence) is thought to result in dissociation and inactivation of the G M /R Gl -PP1 complex (5, 10) . This is readily understood in consideration of the fact that serine 67 of G M /R Gl is found in a sequence motif (-(R/K)-(V/I)-X-F, where X ϭ serine in G M ) that is used by all glycogen-targeting subunits for binding of PP-1. The presence of a consensus protein kinase A phosphorylation site in G M /R Gl is consistent with the potent glycogenolytic effects of forskolin that we observed in G M /R Gl -overexpressing hepatocytes.
Although G L also contains a serine at the position analogous to serine 67 in G M /R Gl , it occurs in the sequence KRVSF instead of RRVSF, which may make it less amenable to phosphorylation by protein kinase A. Thus, it has been suggested that G L is not regulated by a phosphorylation/dephosphorylation mechanism, but rather via allosteric regulation by phosphorylase a (2, 11) . Binding of phosphorylase a to G L reduces the rate at which the G L -PP1 complex dephosphorylates glycogen synthase and glycogen phosphorylase (2, 11) . Studies employing deletion mutants have further suggested that the allosteric effect of phosphorylase a is mediated by its binding to the C-terminal tail of G L , whereas neither PTG or G M /R Gl contain this phosphorylase a binding motif (11) .
In the current study, a vigorous glycogenolytic response to forskolin was observed in G L -overexpressing hepatocytes, accompanied by efficient activation of glycogen phosphorylase and inhibition of glycogen synthase activities. This may indicate that glycogen phosphorylase binds effectively to its allosteric site on G L during stimulation with glycogenolytic agents, resulting in inhibition of the synthase phosphatase and phosphorylase phosphatase activities of PP-1. In forskolin-stimulated cells, this would allow efficient inhibition of glycogen synthase and stimulation of glycogen phosphorylase activities by maintenance of the enzymes in a phosphorylated state. Future studies with G L molecules lacking the putative allosteric binding site for phosphorylase a may be useful for investigation of this model. Another notable differentiating feature of G L -overexpressing cells studied in the absence of forskolin are their enhanced capacity to maintain glycogen synthase in an activated (glucose 6-phosphateindependent) state, relative to PTG-or G M /R Gl -overexpressing cells. This suggests that, under conditions where glycogen phosphorylase a levels are low, G L is more effective than PTG or G M /R Gl at promoting the interaction of glycogen synthase and PP1, resulting in more complete dephosphorylation and activation of glycogen synthase.
PTG contains a valine instead of serine at the amino acid analogous to residue 67 in G M /R Gl , and is therefore not regulated by phosphorylation at this position (3, 4) . The absence of a serine in PTG predicts that glycogenolytic stimuli will be less effective at disrupting the PTG-PP1 complex. This could contribute to the impaired activation of glycogen degradation and glycogen phosphorylase activity that we observed in cells overexpressing PTG. However, regulatory mechanisms in addition to the proximity/activity of PP1 appear to be at work, since glycogen synthase activity state was decreased and immunodetectable phosphorylase a was up-regulated to a similar degree in PTG-, G L -, or G M /R Gl -overexpressing cells by forskolin treatment. Perhaps the binding of phosphorylase a to its allosteric site on G L helps to maintain the enzyme in an active state, possibly by keeping it in close contact with glycogen, which is a known allosteric activator of phosphorylase (26) . In contrast, phosphorylase a in PTG-overexpressing cells may not be as intimately associated with the glycogen particle, and therefore could exhibit a lower intrinsic enzymatic activity. Again, studies with mutant and chimeric PTG and G L constructs may help to address this issue in the future.
In closing, it is interesting to consider the potential therapeutic value of different glycogen-targeting subunits for use in lowering of blood glucose in diabetes. We have recently demonstrated that overexpression of PTG in liver of normal rats improves glucose tolerance without affecting lipid homeostasis (18) . This is in contrast to hepatic overexpression of glucokinase in normal rats, which lowers blood glucose, but also causes dramatic increases in circulating free fatty acids and tri-glycerides (15) . However, overexpression of PTG also blocked hepatic glycogen degradation in fasted rats (18) , consistent with findings in our current and previous (6) in vitro studies. This property of PTG might make animals susceptible to hypoglycemia with prolonged fasting or in response to exercise. G L or G M /R Gl may represent more suitable candidate agents, since their overexpression enhances glycogen deposition in a glucose concentration-dependent fashion, while allowing cells to be fully responsive to glycogenolytic agents. Future studies involving comparison of in vivo effects of overexpressed PTG, G L , and G M /R Gl in normal and diabetic animals will be required to test the validity of these ideas.
